The reason for the distinct outcomes in ribavirin-treated strain 10200-infected mice seen between our study54 and that by Benteet al. 25 is unknown but could be due to differences in mouse strain (IFNAR−/− versus STAT1−/−), challenge dose, or the time treatment was started after infection. The gene discussed is STAT1; the disease is infection.